HIV/AIDS Therapeutics Market to 2018 - Despite Major Patent Expiries, Increased Uptake of Once-a-Day Fixed-dose Combination Drugs to Drive Growth

NEW YORK, Nov. 19, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

HIV/AIDS Therapeutics Market to 2018 - Despite Major Patent Expiries, Increased Uptake of Once-a-Day Fixed-dose Combination Drugs to Drive Growth

http://www.reportlinker.com/p01041698/HIV/AIDS-Therapeutics-Market-to-2018---Despite-Major-Patent-Expiries-Increased-Uptake-of-Once-a-Day-Fixed-dose-Combination-Drugs-to-Drive-Growth.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

HIV/AIDS Therapeutics Market to 2018 - Despite Major Patent Expiries, Increased Uptake of Once-a-Day Fixed-dose Combination Drugs to Drive Growth

Summary GBI Research, a leading business intelligence provider, has released its latest research, "HIV/AIDS Therapeutics Market to 2018 - Despite Major Patent Expiries, Increased Uptake of Once-a-Day Fixed-dose Combination Drugs to Drive Growth". The report provides insights into the Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome) HIV/AIDS therapeutics market including market forecasts up to 2018. It provides an in-depth analysis of the major marketed products, as well as insights into the HIV/AIDS therapeutics R&D pipeline. The report provides in-depth analysis of the unmet needs, drivers and barriers that affect the global HIV/AIDS therapeutics market. The report analyzes the market for HIV/AIDS therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. The report provides branded and generics segmentation in the therapeutic landscape segment. In addition, it analyzes the HIV/AIDS therapeutics market in India, China and Australia. The report discusses the global pipeline for all the HIV/AIDS molecules across various stages of development. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

GBI Research found that the HIV/AIDS therapeutics market in the top seven markets was valued at $13.5 billion in 2011, increasing at a Compound Annual Growth Rate (CAGR) of 12.5% during the 2004–2011 historic period. The market is projected to witness growth of 7% during the 2011–2018 forecast period to reach $21.8 billion. The growth is primarily driven by the increase in the use of single dose multi-class combination drugs such as Atripla, Complera. With the recent launch of Stribild (previously known as Quad), the multi-class combination drugs would drive the market.

Scope

- Annualized market data for the HIV/AIDS therapeutics market from 2004 to 2011, forecast forward to 2018.- Analysis of the HIV/AIDS therapeutics market in the leading geographies of the world, which includes the US, the UK, Germany, France, Italy, Spain, and Japan.- Analysis of the HIV/AIDS therapeutics market in India, China and Australia.- Market characterization of the HIV/AIDS therapeutics market including market size, annual cost of treatment, and treatment usage patterns.- Key drivers and barriers that have a significant impact on the market.- Coverage of pipeline molecules in various phases of drug development.- Competitive benchmarking of leading companies. Key companies studied in this report are Gilead Sciences, Bristol-Myers Squibb, GlaxoSmithKline, Abbott Laboratories, Johnson & Johnson, Merck, and Roche.- Key M&A activities and licensing agreements that have taken place between 2008 and up to June 2012 in the global HIV/AIDS therapeutics market.

Reasons to buy

- Align your product portfolio to the markets with high growth potential.- Develop market-entry and market expansion strategies by identifying the potential region and HIV/AIDS therapeutics market segments poised for strong growth.- Create a more tailored country strategy through the understanding of key drivers and barriers of the global HIV/AIDS therapeutics market.- Develop key strategic initiatives by understanding the key focus areas and top selling products of leading companies.- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.1 Table of Contents1 Table of Contents 51.1 List of Tables 71.2 List of Figures 92 HIV/AIDS Therapeutics Market to 2018 - Introduction 113 HIV/AIDS Therapeutics Market to 2018 - Overview 123.1 Disease Overview 123.1.1 Diagnostic Tests for HIV 133.2 WHO Guidelines for HIV/AIDS Treatment 143.2.1 WHO Clinical Staging of HIV Disease in Adults and Adolescents 153.2.2

Summary

of Changes to the WHO's Guidelines on Initiation of ART based on CD4 Count and Clinical Staging 163.2.3

Summary

of Changes to WHO's Guidelines on First-line Antiretrovirals 173.2.4

Summary

of Changes to the WHO's Guidelines on Second-line Antiretrovirals 183.3 Drugs Classes Used in HIV/AIDS Treatment 193.3.1 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors 193.3.2 Non-nucleoside Reverse Transcriptase Inhibitors 203.3.3 Protease Inhibitors 203.3.4 Fusion Inhibitors 213.3.5 CCR5 Co-receptor Antagonist 213.3.6 Integrase Inhibitors 213.3.7 Multi-class Combination Drugs 223.4 Key Marketed Products 233.4.1 Atripla 233.4.2 Truvada 253.4.3 Reyataz 273.4.4 Sustiva 283.4.5 Isentress 293.5 Advancements in HIV/AIDS Vaccine Research 304 HIV/AIDS Therapeutics Market to 2018 - Market Characterization and Forecast 314.1 Introduction 314.2 Revenue Forecast 324.2.1 Market Share by Drug Class (%), 2011 334.3 Branded Versus Generics Market Share (%), 2011 344.4 Market Share by Company (%), 2011 354.5 Annual Cost of Therapy 364.6 Treatment Usage Pattern 384.6.1 Diseased Population 394.6.2 Diagnosed Population 394.6.3 Prescription Population 394.7 HIV/AIDS Therapeutics Market - Drivers and Restraints 404.7.1 HIV/AIDS Therapeutics Market - Drivers 404.7.2 Market Restraints 425 HIV/AIDS Therapeutics Market to 2018 - The US 455.1 Market Overview 455.2 Revenue Forecast 455.3 Annual Cost of Therapy 465.4 Treatment Usage Pattern 475.4.1 Diseased Population 485.4.2 Diagnosed Population 485.4.3 Prescription Population 486 HIV/AIDS Therapeutics Market to 2018 - Top Five European Countries 496.1 Market Overview 496.2 Revenue Forecast: Top Five European Countries 496.3 Revenue by Geographical Segmentation 506.4 Annual Cost of Therapy 516.5 Treatment Usage Pattern 526.5.1 Diseased Population 536.5.2 Diagnosed Population 536.5.3 Prescription Population 537 HIV/AIDS Therapeutics Market to 2018 - Japan 547.1 Market Overview 547.2 Revenue Forecast 547.3 Annual Cost of Therapy 557.4 Treatment Usage Pattern 567.4.1 Diseased Population 577.4.2 Diagnosed Population 577.4.3 Prescription Population 578 HIV/AIDS Therapeutics Market to 2018 - Emerging Markets 588.1 China 588.1.1 Epidemiology 588.1.2 Important Events in China's HIV/AIDS Policy Development 598.1.3 Clinical Trials in China 608.2 India 618.2.1 Overview 618.2.2 National AIDS Control Programs 638.2.3 Treatment Guidelines 648.2.4 Trade Related Aspects of Intellectual Property Rights Agreement and its Impact on Generics 658.2.5 Recent Developments in HIV/AIDS Therapeutics Market in India 658.3 Australia 668.3.1 Overview 668.3.2 Highly Specialized Drugs (Section 100) Program 679 HIV/AIDS Therapeutics Market to 2018 - Pipeline Analysis 709.1 Overview 709.2 Promising Molecules in Late Stages of Clinical Development 719.2.1 Stribild (Quad) 719.2.2 Cobicistat 739.2.3 JTK-303 749.2.4 1349572 759.2.5 572-Trii 7610 HIV/AIDS Therapeutics Market to 2018 - Competitive Landscape 7810.1 Introduction 7810.2 Major Company Profiles 7910.2.1 Gilead Sciences, Inc 7910.2.2 GlaxoSmithKline (GSK) 8010.2.3 BMS 8210.2.4 Abbott Laboratories 8310.2.5 Merck 8410.2.6 Johnson & Johnson (J&J) 8510.2.7 Roche 8611 HIV/AIDS Therapeutics Market to 2018 - Strategic Consolidations 8711.1 Deals by Year 8711.2 Deals by Type 8811.2.1 Deals by Value 9711.3 Deals by Geography 9811.4

Summary

of Major M&A Deals 9911.4.1 Daiichi Sankyo Acquires Majority Stake in Ranbaxy Labs 9911.4.2 Endo Pharma Acquires Indevus Pharma 9911.5

Summary

of Major Licensing Deals 9911.5.1 GlaxoSmithKline Enters into Licensing Agreement with Idenix Pharma 9911.5.2 BMS Enters into Licensing Agreement with Oncolys BioPharma 9911.6

Summary

of Major Partnerships 10011.6.1 GlaxoSmithKline Enters into an Agreement with Concert Pharma 10011.6.2 Chemrar Enters into Joint Venture Agreement with Rusnano 10011.6.3 GenVec Enters into an Agreement with SAIC-Frederick 10012 HIV/AIDS Therapeutics Market to 2018 - Appendix 10112.1 Market Definitions 10112.2 Abbreviations 10112.3 Bibliography 10312.4 Research Methodology 10512.4.1 Coverage 10512.4.2 Secondary Research 10612.4.3 Primary Research 10612.5 Therapeutic Landscape 10712.5.1 Epidemiology-based Forecasting 10712.5.2 Market Size by Geography 10912.6 Geographical Landscape 10912.7 Pipeline Analysis 11012.8 Competitive Landscape 11012.8.1 Expert Panel Validation 11012.9 Contact Us 11012.10 Disclaimer 111

1.1 List of Tables

Table 1: HIV/AIDS Therapeutics Market to 2018, WHO Clinical Staging of HIV Disease in Adults and Adolescents, 2010 15Table 2: HIV/AIDS Therapeutics Market to 2018,

Summary

of Changes to the WHO's Guidelines on Initiation of Antiretroviral Therapy Based on CD4 Count and Clinical Staging, 2010 16Table 3: HIV/AIDS Therapeutics Market to 2018,

Summary

of Changes to WHO's Guidelines on First-line Antiretrovirals, 2010 17Table 4: HIV/AIDS Therapeutics Market to 2018,

Summary

of Changes to WHO's Guidelines on Second-line Antiretrovirals, 2010 18Table 5: HIV/AIDS Therapeutics Market to 2018, Nucleoside/Nucleotide Reverse Transcriptase Inhibitors, Global Sales ($m), 2011 19Table 6: HIV/AIDS Therapeutics Market to 2018, Non-Nucleoside Reverse Transcriptase Inhibitors, Global Sales ($m), 2011 20Table 7: HIV/AIDS Therapeutics Market to 2018, Protease Inhibitors, Global Sales ($m), 2011 20Table 8: HIV/AIDS Therapeutics Market to 2018, Fusion Inhibitors, Global Sales ($m), 2011 21Table 9: HIV/AIDS Therapeutics Market to 2018, CCR5 Co-receptor Antagonist Global Sales ($m), 2011 21Table 10: HIV/AIDS Therapeutics Market to 2018, Integrase Inhibitors Global Sales ($m), 2011 21Table 11: HIV/AIDS Therapeutics Market to 2018, Multi-class Combination Drugs, Global Sales ($m), 2011 22Table 12: HIV/AIDS Therapeutics Market to 2018, Global, Market Share of Key Products (%), 2011 23Table 13: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Revenue ($bn), 2004-2011 32Table 14: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Revenue Forecast ($bn), 2011-2018 32Table 15: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Annual Cost of Therapy ($), 2004-2011 36Table 16: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Annual Cost of Therapy Forecast ($), 2011-2018 36Table 17: HIV/AIDS Therapeutics Market, Top Seven Markets, Treatment Usage Pattern ('000), 2004-2011 38Table 18: HIV/AIDS Therapeutics Market, Top Seven Markets, Treatment Usage Pattern Forecast ('000), 2011-2018 38Table 19: HIV/AIDS Therapeutics Market to 2018, The US, Patent Expiries, 2012-2018 44Table 20: HIV/AIDS Therapeutics Market to 2018, The US, Revenue ($bn), 2004-2011 45Table 21: HIV/AIDS Therapeutics Market to 2018, The US, Revenue Forecast ($bn), 2011-2018 45Table 22: HIV/AIDS Therapeutics Market to 2018, The US, Annual Cost of Therapy ($), 2004-2011 46Table 23: HIV/AIDS Therapeutics Market to 2018, The US, Annual Cost of Therapy Forecast ($), 2011-2018 46Table 24: HIV/AIDS Therapeutics Market to 2018, The US, Treatment Usage Pattern ('000), 2004-2011 47Table 25: HIV/AIDS Therapeutics Market to 2018, The US, Treatment Usage Pattern Forecast ('000), 2011-2018 47Table 26: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Revenue ($bn), 2004-2011 49Table 27: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Revenue Forecast ($bn), 2011-2018 49Table 28: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Revenue by Geographical Segmentation ($m), 2004-2011 50Table 29: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Revenue Forecast by Geographical Segmentation ($m), 2011-2018 50Table 30: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Annual Cost of Therapy ($), 2004-2011 51Table 31: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Annual Cost of Therapy Forecast ($), 2011-2018 51Table 32: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Treatment Usage Pattern ('000), 2004-2011 52Table 33: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Treatment Usage Pattern Forecast ('000), 2011-2018 52Table 34: HIV/AIDS Therapeutics Market to 2018, Japan, Revenue ($m), 2004-2011 54Table 35: HIV/AIDS Therapeutics Market to 2018, Japan, Revenue Forecast ($m), 2011-2018 54Table 36: HIV/AIDS Therapeutics Market to 2018, Japan, Annual Cost of Therapy ($), 2004-2011 55Table 37: HIV/AIDS Therapeutics Market to 2018, Japan, Annual Cost of Therapy Forecast ($), 2011-2018 55Table 38: HIV/AIDS Therapeutics Market to 2018, Japan, Treatment Usage Pattern ('000), 2004-2011 56Table 39: HIV/AIDS Therapeutics Market to 2018, Japan, Treatment Usage Pattern Forecast ('000), 2011-2018 56Table 40:HIV/AIDS Therapeutics Market, China, Diseased Population ('000), 2005-2011 58Table 41: HIV/AIDS Therapeutics Market, Pipeline Molecules, China, 2012 60Table 42: HIV/AIDS Therapeutics Market to 2018, India, ART Centre Coverage and Patients on First-line Therapy, 2005-2010 62Table 43: HIV/AIDS Therapeutics Market to 2018, India, HIV/AIDS Prevalence, 2004-2009 62Table 44: HIV/AIDS Therapeutics Market to 2018, India, Treatment Guidelines, 2011 64Table 45: HIV/AIDS Therapeutics Market to 2018, Australia, Number of HIV Cases and MSM (%), 2001-2010 66Table 46: HIV/AIDS Therapeutics Market to 2018, Australia, List of Approved Medications Under Highly Specialized Drugs (Section 100) Program, 2012 68Table 47: HIV/AIDS Therapeutics Market to 2018, Australia, Number of People Prescribed ART through the Highly Specialized Drugs (S100) Program, 2006-2010 69Table 48: HIV Therapeutics Market, Global, Number of Molecules in Pipeline by Phase, 2012 70Table 49: HIV Therapeutics Market, Global, Promising Molecules in Late Stages of Clinical Development, 2012 71Table 50: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Deals by Type, 2008-2012 88Table 51: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Mergers and Acquisitions Deals, 2008-2012 89Table 52: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Partnership Deals, 2008-2012 90Table 53: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Partnership Deals, 2008-2012 92Table 54: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Licensing Deals, 2008-2012 93Table 55: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Licensing Deals, 2008-2012 94Table 56: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Licensing Deals, 2008-2012 95Table 57: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Deals by Value ($m), 2008-2012 97Table 58: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Deals by Geography, 2008-2012 98

1.2 List of Figures

Figure 1: HIV/AIDS Therapeutics Market to 2018, Global, Treatment Algorithm, 2012 13Figure 2: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Revenue Forecast ($bn), 2004-2018 32Figure 3: HIV/AIDS Therapeutics Market to 2018, Global, Market Share by Drug Class (%), 2011 33Figure 4: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Branded Versus Generics Market Share (%), 2011 34Figure 5: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Market Share by Company (%), 2011 35Figure 6: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Annual Cost of Therapy ($), 2004-2018 36Figure 7: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Treatment Usage Pattern ('000), 2004-2018 38Figure 8: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Drivers and Restraints, 2012 40Figure 9: HIV/AIDS Therapeutics Market to 2018, The US, Revenue Forecast ($bn), 2004-2018 45Figure 10: HIV/AIDS Therapeutics Market to 2018, The US, Annual Cost of Therapy ($), 2004-2018 46Figure 11: HIV/AIDS Therapeutics Market to 2018, The US, Treatment Usage Pattern ('000), 2004-2018 47Figure 12: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Revenue Forecast ($bn), 2004-2018 49Figure 13: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Revenue Forecast by Geographical Segmentation ($m), 2004-2018 50Figure 14: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Annual Cost of Therapy Forecast ($), 2004-2018 51Figure 15: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Treatment Usage Pattern ('000), 2004-2018 52Figure 16: HIV/AIDS Therapeutics Market to 2018, Japan, Revenue Forecast ($m), 2004-2018 54Figure 17: HIV/AIDS Therapeutics Market to 2018, Japan, Annual Cost of Therapy ($), 2004-2018 55Figure 18: HIV/AIDS Therapeutics Market to 2018, Japan, Treatment Usage Pattern ('000), 2004-2018 56Figure 19: HIV/AIDS Therapeutics Market, China, Diseased Population ('000), 2005-2011 58Figure 20: HIV/AIDS Therapeutics Market, Important Events in China's HIV/AIDS Policy Development, 1985-2012 59Figure 21: HIV/AIDS Therapeutics Market to 2018, India, ART Centre Coverage and Patients on First Line Therapy, 2005-2010 61Figure 22: HIV/AIDS Therapeutics Market to 2018, India, HIV/AIDS Prevalence, 2004-2009 62Figure 23: HIV/AIDS Therapeutics Market to 2018, Australia, Number of Diagnosed HIV Cases and MSM (%), 2001-2010 66Figure 24: HIV/AIDS Therapeutics Market to 2018, Global, Pipeline by Phase (%), 2012 70Figure 25: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Market Share by Company (%), 2011 78Figure 26: HIV/AIDS Therapeutics Market to 2018, Gilead Sciences, SWOT Analysis, 2012 79Figure 27: HIV/AIDS Therapeutics Market to 2018, GSK, SWOT Analysis, 2012 81Figure 28: HIV/AIDS Therapeutics Market to 2018, BMS, SWOT Analysis, 2012 82Figure 29: HIV/AIDS Therapeutics Market to 2018, Abbott, SWOT Analysis, 2012 83Figure 30: HIV/AIDS Therapeutics Market to 2018, Merck, SWOT Analysis, 2012 84Figure 31: HIV/AIDS Therapeutics Market to 2018, J&J, SWOT Analysis, 2012 85Figure 32: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Deals by Year, 2008-2012 87Figure 33: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Deals by Type (%), 2008-2012 88Figure 34: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Deals by Value (%), 2008-2012 97Figure 35: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Deals by Geography (%), 2008-2012 98Figure 36: GBI Research Market Forecasting Model 109

Companies mentioned

Gilead Sciences, Inc

GlaxoSmithKline (GSK)

BMS

Abbott Laboratories

Merck

Johnson & Johnson (J&J)

Roche

To order this report:Therapy Industry: HIV/AIDS Therapeutics Market to 2018 - Despite Major Patent Expiries, Increased Uptake of Once-a-Day Fixed-dose Combination Drugs to Drive Growth

 

Nicolas Bombourg
Reportlinker
Email:
nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.